CRISPR Therapeutics CEO Presents at Jefferies and William Blair Investor Conferences — Casgevy Commercial Ramp, CTX310 Cardiovascular Phase 1, and Allogeneic CAR-T Pipeline

CRISPR Therapeutics (CRSP) senior management, including CEO Samarth Kulkarni, presented at two major investor conferences on June 3, 2026: the Jefferies Global Healthcare Conference (New York, 9:55 a.m. ET) and William Blair's 46th Annual Growth Stock Conference (Chicago, 4:40 p.m. CT). The presentations covered the company's diversified pipeline across hemoglobinopathies, cardiovascular disease, oncology, autoimmune disease, and regenerative medicine. Key commercial and pipeline highlights: (1) Casgevy commercial ramp — 500+ patients have initiated the treatment journey globally as of Q1 2026, $43M Q1 2026 net revenue, ~90% US commercial insurance coverage, and 45+ authorized treatment centers (ATCs) active worldwide. The pediatric sBLA for Casgevy (ages 5–11, SCD and TDT) is under FDA review with a Commissioner's National Priority Voucher. (2) CTX310 — a Phase 1 in vivo CRISPR cardiovascular program targeting ANGPTL3 for dyslipidemia/hypertriglyceridemia; Phase 1b dose escalation ongoing with initial data expected in 2026. (3) Allogeneic CAR-T programs: CTX340 (next-gen anti-CD19, CD70 and TRAC-deleted) and CTX460 (BCMA-targeted) are advancing toward clinical readiness in H2 2026–2027. (4) SyNTase editing platform — the company's proprietary precision gene insertion technology for regenerative medicine applications was highlighted as a longer-term pipeline driver. CRISPR Therapeutics held $2.44B cash on hand as of Q1 2026, providing runway through pipeline expansion. A third investor presentation is scheduled for the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026 at 2:40 p.m. ET.